Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 20
Study Overview
Brief Summary
de Boer NL, van Kooten JP, Burger JWA, Verhoef C, Aerts J, Madsen EVE. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. BMJ Open. 2019;9(5):e026779. van Kooten JP, de Boer NL, Burger JWA, Verhoef C, Aerts J, Madsen EVE. Adjuvante Dendritische Cel Immunotherapie na Cytoreductieve Chirurgie en Hypertherme Intraperitoneale Chemotherapie voor patiënten met Maligne Peritoneaal Mesothelioom. De MESOPEC studie. Nederlands Tijdschrift voor Oncologie. Jaargang 16, Nummer 2, Maart 2019.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria, before undergoing CRS-HIPEC:
- •Patients with a histologically or cytologically confirmed diagnosis of malignant peritoneal mesothelioma
Exclusion Criteria
- •A potential participant who meets any of the following criteria will be excluded from participation in the study:
- •Extra-abdominal disease/ metastatic disease
